Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8157044,half life,"There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1).",Pharmacokinetics of chlorpromazine and key metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157044/),h,11.05,2579,DB00477,Chlorpromazine
,8157044,volume of distribution,"There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1).",Pharmacokinetics of chlorpromazine and key metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157044/),l,1215,2580,DB00477,Chlorpromazine
,8157044,volume of distribution at steady state,"There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1).",Pharmacokinetics of chlorpromazine and key metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157044/),l,642,2581,DB00477,Chlorpromazine
,8157044,mean residence time,"There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1).",Pharmacokinetics of chlorpromazine and key metabolites. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157044/),h,8.88,2582,DB00477,Chlorpromazine
,8157044,systemic clearance,"There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1).",Pharmacokinetics of chlorpromazine and key metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157044/),[l] / [h],76.6,2583,DB00477,Chlorpromazine
,8583393,conversion ratio,"Closer scrutiny discloses a conversion ratio of parent compound to N-desmethyl metabolite of 1.1 for chlorpromazine and of 2.2 for chlorimipramine, indicating the greater efficiency of chlorimipramine metabolism in all compartments.","Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,1.1,3139,DB00477,Chlorpromazine
,8583393,conversion ratio,"Closer scrutiny discloses a conversion ratio of parent compound to N-desmethyl metabolite of 1.1 for chlorpromazine and of 2.2 for chlorimipramine, indicating the greater efficiency of chlorimipramine metabolism in all compartments.","Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,2.2,3140,DB00477,Chlorpromazine
,8583393,conversion index,The expected high conversion index found in the liver (2.3) reaches its maximum of 5.4 in the lung.,"Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,2.3,3141,DB00477,Chlorpromazine
,8583393,conversion index,The expected high conversion index found in the liver (2.3) reaches its maximum of 5.4 in the lung.,"Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,5.4,3142,DB00477,Chlorpromazine
,25996834,oral bioavailability,"Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%.",In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996834/),%,37,16839,DB00477,Chlorpromazine
,25996834,bioavailability,"It needs to be combined with ritonavir, which increases the bioavailability to 82%.",In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996834/),%,82,16840,DB00477,Chlorpromazine
,25996834,apparent permeability,Ex-vivo apparent permeability of the freeze-dried SLN across everted rat intestine was 24 × 10-6 at 37 °C and 5.6 × 10-6 at 4 °C.,In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996834/),,24 × 10-6,16841,DB00477,Chlorpromazine
,25996834,apparent permeability,Ex-vivo apparent permeability of the freeze-dried SLN across everted rat intestine was 24 × 10-6 at 37 °C and 5.6 × 10-6 at 4 °C.,In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996834/),,5.6 × 10-6,16842,DB00477,Chlorpromazine
,25996834,AUC,"In-vivo pharmacokinetic studies on rats demonstrated increase in the AUC of SLN (26) as compared to that of marketed tablet (13.22), while the presence of lymphatic uptake inhibitor cycloheximide lowered the AUC of SLN to 17.19 which further led credence to the involvement of lymphatic uptake behind improved bioavailability.",In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996834/),,17.19,16843,DB00477,Chlorpromazine
,6748379,detection limit,The detection limit of CPZ was 0.5 ng for one chromatographic injection.,Determination of chlorpromazine in the blood and brain of mice by high performance liquid chromatography combined with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748379/),ng,0.5,22000,DB00477,Chlorpromazine
,6748379,biological half life,"The biological half life was estimated to be 87 and 65 min, in the blood and brain, respectively.",Determination of chlorpromazine in the blood and brain of mice by high performance liquid chromatography combined with electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748379/),min,87,22001,DB00477,Chlorpromazine
,6748379,biological half life,"The biological half life was estimated to be 87 and 65 min, in the blood and brain, respectively.",Determination of chlorpromazine in the blood and brain of mice by high performance liquid chromatography combined with electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748379/),min,65,22002,DB00477,Chlorpromazine
,849674,biologic availability,"The biologic availability of single oral doses relative to single intramuscular doses ranged from 10 to 69%, and was on average 32%.",Pharmacokinetics of chlorpromazine after single and chronic dosage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/849674/),%,10 to 69,25910,DB00477,Chlorpromazine
,849674,biologic availability,"The biologic availability of single oral doses relative to single intramuscular doses ranged from 10 to 69%, and was on average 32%.",Pharmacokinetics of chlorpromazine after single and chronic dosage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/849674/),%,32,25911,DB00477,Chlorpromazine
,8147942,absolute bioavailability,"the distribution-free confidence intervals for the absolute bioavailability of the three phenothiazines were within 10.5 to 24.7% for chlorpromazine, 7.8 to 24.9% for promazine and 12.3 to 40% for promethazine.","[Absolute bioavailability of chlorpromazine, promazine and promethazine]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147942/),%,10.5 to 24.7,26022,DB00477,Chlorpromazine
,8147942,absolute bioavailability,"the distribution-free confidence intervals for the absolute bioavailability of the three phenothiazines were within 10.5 to 24.7% for chlorpromazine, 7.8 to 24.9% for promazine and 12.3 to 40% for promethazine.","[Absolute bioavailability of chlorpromazine, promazine and promethazine]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147942/),%,7.8 to 24.9,26023,DB00477,Chlorpromazine
,8147942,absolute bioavailability,"the distribution-free confidence intervals for the absolute bioavailability of the three phenothiazines were within 10.5 to 24.7% for chlorpromazine, 7.8 to 24.9% for promazine and 12.3 to 40% for promethazine.","[Absolute bioavailability of chlorpromazine, promazine and promethazine]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147942/),%,12.3 to 40,26024,DB00477,Chlorpromazine
,6634924,relative bioavailability,"With reference to the standard preparation, the cellulose-containing preparations have a relative bioavailability of 38.8 and 45.7%, respectively.",[Pharmaceutical and biologic availability of chlorpromazine from macromolecule-containing tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6634924/),%,38.8,34739,DB00477,Chlorpromazine
,6634924,relative bioavailability,"With reference to the standard preparation, the cellulose-containing preparations have a relative bioavailability of 38.8 and 45.7%, respectively.",[Pharmaceutical and biologic availability of chlorpromazine from macromolecule-containing tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6634924/),%,45.7,34740,DB00477,Chlorpromazine
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],33.2,40333,DB00477,Chlorpromazine
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],27.1,40334,DB00477,Chlorpromazine
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,15.4,40335,DB00477,Chlorpromazine
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,13.5,40336,DB00477,Chlorpromazine
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],7.18,40337,DB00477,Chlorpromazine
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],8.32,40338,DB00477,Chlorpromazine
,24241722,molar extinction coefficients,All the tested PTZs exhibited potent UVA/B absorption with molar extinction coefficients of ca. 3400-4400 M(-1)cm(-1).,Photosafety screening of phenothiazine derivatives with combined use of photochemical and cassette-dosing pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24241722/),1/[M],3400-4400,47219,DB00477,Chlorpromazine
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,248.63,50518,DB00477,Chlorpromazine
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,254.23,50519,DB00477,Chlorpromazine
,31376827,oral bioavailability,"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal.","Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,4,51274,DB00477,Chlorpromazine
,31376827,oral bioavailability,"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal.","Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,15,51275,DB00477,Chlorpromazine
,31376827,entrapment efficiency,Optimized formulation of SLN showed particle size of 233 ± 42 nm and entrapment efficiency of 87.4 ± 1.29%.,"Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,87.4,51276,DB00477,Chlorpromazine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,92,58594,DB00477,Chlorpromazine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,98,58595,DB00477,Chlorpromazine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,15,58596,DB00477,Chlorpromazine
,7658345,peak concentration (Cmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[ng] / [ml],7.15,67443,DB00477,Chlorpromazine
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67444,DB00477,Chlorpromazine
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67445,DB00477,Chlorpromazine
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67446,DB00477,Chlorpromazine
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67447,DB00477,Chlorpromazine
,7658345,area under the curve from 0 to 72 h (AUC0-72),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[h·ng] / [ml],201,67448,DB00477,Chlorpromazine
,432106,half-life,"The pharmacokinetics studies in 48 experiments on the animals of different ages showed that the half-life of CPZ in kids (new born, 1 week and 3 weeks old) and goats (3 months old and adult animals) ranged from 1.47 to 1.86 hour while distribution half-life was only 0.11 to 0.17 hour.","Spectrofluorometric assay of chlorpromazine, half-life and pharmacokinetics of chlorpromazine in goats of different ages. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432106/),h,1.47 to 1.86,115239,DB00477,Chlorpromazine
,432106,distribution half-life,"The pharmacokinetics studies in 48 experiments on the animals of different ages showed that the half-life of CPZ in kids (new born, 1 week and 3 weeks old) and goats (3 months old and adult animals) ranged from 1.47 to 1.86 hour while distribution half-life was only 0.11 to 0.17 hour.","Spectrofluorometric assay of chlorpromazine, half-life and pharmacokinetics of chlorpromazine in goats of different ages. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432106/),h,0.11 to 0.17,115240,DB00477,Chlorpromazine
higher,432106,Volume of distribution,Volume of distribution of CPZ in kids and goats was much higher than 1 which indicated that the drug was extensively localized in the tissues.,"Spectrofluorometric assay of chlorpromazine, half-life and pharmacokinetics of chlorpromazine in goats of different ages. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432106/),,1,115241,DB00477,Chlorpromazine
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00477,Chlorpromazine
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00477,Chlorpromazine
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00477,Chlorpromazine
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00477,Chlorpromazine
excess,3342470,maximum tolerated dose,"A maximum tolerated dose was not defined; however, the projected maximum tolerated dose appears to be in excess of 450 mg/m2.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),[mg] / [m2],450,129935,DB00477,Chlorpromazine
,3342470,t 1/2,"The drug is rapidly cleared from plasma (t 1/2 = 3 h), and its volume of distribution is approximately twice that of total body water in children.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),h,3,129936,DB00477,Chlorpromazine
,8824688,half-life,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),h,1.1 and 16.8,156673,DB00477,Chlorpromazine
,8824688,clearance,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),1/[(m)^2·h],1.2 and 10.61,156674,DB00477,Chlorpromazine
,8824688,volume of distribution,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),[1] / [kg],0.26 and 1.48,156675,DB00477,Chlorpromazine
,8824688,clearance,4. Children who had received prior treatment with dexamethasone showed a mean increase in clearance of 2.51 h-1 m-2 (P = 0.001) presumably as a result of CYP450 enzyme induction.,Cyclophosphamide pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),1/[(m)^2·h],2.51,156676,DB00477,Chlorpromazine
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,2,169917,DB00477,Chlorpromazine
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,0.05,169918,DB00477,Chlorpromazine
,7349328,elimination half-life,"Based on total (free and bound) chlorpromazine levels in plasma, pseudo-distribution equilibrium was rapidly attained, and the elimination half-life was 1.51 +/- 0.48 h (mean +/- SD, n = 8).",Pharmacokinetics and dosage of chlorpromazine in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349328/),h,1.51,181024,DB00477,Chlorpromazine
,7349328,Total body clearance,"Total body clearance, which is the sum of all clearance processes, was 80 +/- 25 ml/min/kg.",Pharmacokinetics and dosage of chlorpromazine in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349328/),[ml] / [kg·min],80,181025,DB00477,Chlorpromazine
,7903373,area under the plasma concentration-time curve (AUC0-24),"Ingestion of chlorimipramine resulted in an area under the plasma concentration-time curve (AUC0-24) for parent drug plus metabolites 5-fold higher than that observed in the same subjects following chlorpromazine intake (600 +/- 87 and 124 +/- 14 ng mL-1, respectively).","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],600,186589,DB00477,Chlorpromazine
,7903373,area under the plasma concentration-time curve (AUC0-24),"Ingestion of chlorimipramine resulted in an area under the plasma concentration-time curve (AUC0-24) for parent drug plus metabolites 5-fold higher than that observed in the same subjects following chlorpromazine intake (600 +/- 87 and 124 +/- 14 ng mL-1, respectively).","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],124,186590,DB00477,Chlorpromazine
,7903373,peak value,"Plasma chlorimipramine levels reached a mean peak value of 43.8 ng mL-1, which occurred 2 h after administration.","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],43.8,186591,DB00477,Chlorpromazine
<,8489555,bioavailability,"However, the bioavailability was low in the rodents (< 10% in mice and hamsters and < 1% in rats) due to an extensive first-pass elimination in the hepato-portal system.",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,10,206092,DB00477,Chlorpromazine
<,8489555,bioavailability,"However, the bioavailability was low in the rodents (< 10% in mice and hamsters and < 1% in rats) due to an extensive first-pass elimination in the hepato-portal system.",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,1,206093,DB00477,Chlorpromazine
>,8489555,bioavailability,"In dogs and humans, clearance values were low and the bioavailability high (> 90%).",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,90,206094,DB00477,Chlorpromazine
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],3-6,206095,DB00477,Chlorpromazine
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],1.6,206096,DB00477,Chlorpromazine
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],0.7,206097,DB00477,Chlorpromazine
,8489555,t1/2,Studies in dogs with 14C-remoxipride showed that the compound was rapidly distributed to tissues and eliminated at rates similar to that in plasma (t1/2 3-4 h).,Disposition of remoxipride in different species. Species differences in metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),h,3-4,206098,DB00477,Chlorpromazine
,32187715,V1 /Vdss,Twenty compounds that have a human V1 /Vdss of 0.053-0.66 were selected from the literature.,"Applicability of the Øie-Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187715/),,0.053-0.66,232486,DB00477,Chlorpromazine
>,24732149,m,The ion transitions monitored in positive-ion mode [M+H](+) of multiple-reaction monitoring (MRM) were m/z 387>126 for mesoridazine and m/z 319>86 for IS.,Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),,38,235486,DB00477,Chlorpromazine
>,24732149,m/z,The ion transitions monitored in positive-ion mode [M+H](+) of multiple-reaction monitoring (MRM) were m/z 387>126 for mesoridazine and m/z 319>86 for IS.,Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),,319,235487,DB00477,Chlorpromazine
>,24732149,m/z,The ion transitions monitored in positive-ion mode [M+H](+) of multiple-reaction monitoring (MRM) were m/z 387>126 for mesoridazine and m/z 319>86 for IS.,Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),,86,235488,DB00477,Chlorpromazine
≥,24732149,signal-to-noise ratios,The detector response was specific and linear for mesoridazine at concentrations within the range 0.001-4μg/ml and the correlation coefficient (R(2)) was greater than 0.999 and the signal-to-noise ratios for the samples were ≥10.,Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),,10,235489,DB00477,Chlorpromazine
,24732149,matrix effects,"The matrix effects were approximately 101 and 99.5% from rat plasma for mesoridazine and chlorpromazine, respectively.",Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),%,101,235490,DB00477,Chlorpromazine
,24732149,matrix effects,"The matrix effects were approximately 101 and 99.5% from rat plasma for mesoridazine and chlorpromazine, respectively.",Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732149/),%,99.5,235491,DB00477,Chlorpromazine
,21429493,recoveries,The recoveries of the five phenothiazines spiked into plasma were 91-95% and the limits of quantification for each drug were between 0.25 and 2.0 ng/0.1 mL.,Quantitative determination of phenothiazine derivatives in human plasma using monolithic silica solid-phase extraction tips and gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21429493/),%,91-95,238460,DB00477,Chlorpromazine
,21429493,recoveries,The recoveries of the five phenothiazines spiked into plasma were 91-95% and the limits of quantification for each drug were between 0.25 and 2.0 ng/0.1 mL.,Quantitative determination of phenothiazine derivatives in human plasma using monolithic silica solid-phase extraction tips and gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21429493/),[ng] / [0.1],0.25 and 2.0,238461,DB00477,Chlorpromazine
,3385601,brain to plasma concentration ratio,The brain to plasma concentration ratio of pentobarbital was 1.5 and was almost constant during the experiment.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),,1.5,245163,DB00477,Chlorpromazine
,3385601,hepatic intrinsic clearance,The hepatic intrinsic clearance of pentobarbital was decreased from 0.438 to 0.331 l/h by chlorpromazine coadministration.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),[l] / [h],0.438,245164,DB00477,Chlorpromazine
,3385601,hepatic intrinsic clearance,The hepatic intrinsic clearance of pentobarbital was decreased from 0.438 to 0.331 l/h by chlorpromazine coadministration.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),[l] / [h],0.331,245165,DB00477,Chlorpromazine
,19239733,limit of detection,The assay was linear over the range of 0.05 to 2.0 microg/g and the limit of detection was 0.01 microg/g for CHX in whole blood.,High-performance liquid chromatographic determination of chlorhexidine in whole blood by solid-phase extraction and kinetics following an intravenous infusion in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239733/),[μg] / [g],0.01,261228,DB00477,Chlorpromazine
,19239733,recoveries,"At the concentration range of 0.05 to 2.0 microg/g, the recoveries ranged from 72% to 85%, and the intra- and interday precision, expressed as coefficient of variation, were less than 11% and 13%, respectively.",High-performance liquid chromatographic determination of chlorhexidine in whole blood by solid-phase extraction and kinetics following an intravenous infusion in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239733/),%,72,261229,DB00477,Chlorpromazine
,19239733,recoveries,"At the concentration range of 0.05 to 2.0 microg/g, the recoveries ranged from 72% to 85%, and the intra- and interday precision, expressed as coefficient of variation, were less than 11% and 13%, respectively.",High-performance liquid chromatographic determination of chlorhexidine in whole blood by solid-phase extraction and kinetics following an intravenous infusion in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239733/),%,85,261230,DB00477,Chlorpromazine
,19239733,alpha half-life (of distribution),The kinetic profiles of CHX conformed to a two-compartment model with an alpha half-life (of distribution) at 0.05 h and a beta half-life (of elimination) at 0.55 h in rats.,High-performance liquid chromatographic determination of chlorhexidine in whole blood by solid-phase extraction and kinetics following an intravenous infusion in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239733/),h,0.05,261231,DB00477,Chlorpromazine
,19239733,beta half-life (of elimination),The kinetic profiles of CHX conformed to a two-compartment model with an alpha half-life (of distribution) at 0.05 h and a beta half-life (of elimination) at 0.55 h in rats.,High-performance liquid chromatographic determination of chlorhexidine in whole blood by solid-phase extraction and kinetics following an intravenous infusion in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239733/),h,0.55,261232,DB00477,Chlorpromazine
,2906159,Tmax,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,4-6,268579,DB00477,Chlorpromazine
,2906159,biological half-life,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,56-88,268580,DB00477,Chlorpromazine
,6646875,half-life,"The kinetics of plasma chlorpromazine removal were described with a two-compartment model, exhibiting a rapid half-life of 1.46 days and a slow half-life of 3.19 days.",Chlorpromazine excretion by the neonate following chronic in utero exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6646875/),d,1.46,268869,DB00477,Chlorpromazine
,6646875,half-life,"The kinetics of plasma chlorpromazine removal were described with a two-compartment model, exhibiting a rapid half-life of 1.46 days and a slow half-life of 3.19 days.",Chlorpromazine excretion by the neonate following chronic in utero exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6646875/),d,3.19,268870,DB00477,Chlorpromazine
,22074958,flow-rate,The mobile phase was a mixture of 65% water+1% formic acid and 35% of acetonitrile at a flow-rate of 0.5 mL/min.,Chlorpromazine quantification in human plasma by UPLC-electrospray ionization tandem mass spectrometry. Application to a comparative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22074958/),[ml] / [min],0.5,269924,DB00477,Chlorpromazine
